Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

46
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
46
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

34
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
34
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

69
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
69
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

243
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
243
Antibiotic Selection00:57

Antibiotic Selection

62.1K
Overview
62.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The costs and health outcomes associated with a personalised antibiotic combination testing service for carbapenem-resistant Pseudomonas aeruginosa: A cost-effectiveness analysis.

International journal of antimicrobial agents·2026
Same author

The Early Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients with Early Breast Cancer.

ClinicoEconomics and outcomes research : CEOR·2026
Same author

VAMP7-mediated autophagy regulates cervical cancer progression associated with persistent HPV16 infection.

Clinical and translational medicine·2026
Same author

Seven-Day vs Four-Day Infusion Set Replacement Interval and Catheter-Related Infections.

JAMA network open·2025
Same author

Mapping the Children's Dermatology Life Quality Index Questionnaire to EQ-5D-Y-3L in Pediatric Patients With Atopic Dermatitis.

Value in health regional issues·2025
Same author

Elevated VAMP8 expression promotes cervical cancer progression by enhancing autophagy via HIF-1 pathway.

BMC medicine·2025

Related Experiment Video

Updated: Mar 31, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

28.0K

Polymyxin B versus colistin: an update.

Yiying Cai1,2, Winnie Lee1, Andrea L Kwa1,3,2

  • 1a 1 Department of Pharmacy, Singapore General Hospital, Outram Rd 169608, Singapore.

Expert Review of Anti-Infective Therapy
|October 22, 2015
PubMed
Summary
This summary is machine-generated.

Polymyxin B and colistin are polypeptide antibiotics with distinct differences in potency and administration. Understanding these variations is crucial for effective use against multi-drug resistant bacteria.

Keywords:
colistimethate sodiumcolistin sulfatemulti-drug resistancepharmacokinetics and pharmacodynamicspolymyxin Bpolymyxin combination therapypolymyxinspolypeptide antibiotics

More Related Videos

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

11.6K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.7K

Related Experiment Videos

Last Updated: Mar 31, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

28.0K
Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

11.6K
Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.7K

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Polymyxin B and colistin (polymyxin E) are older polypeptide antibiotics with significant toxicity.
  • Previously considered equivalent, recent findings highlight key differences between polymyxin B and colistin.
  • Their re-emergence is driven by the rise of multi-drug resistant Gram-negative infections.

Purpose of the Study:

  • To review and compare polymyxin B and colistin, focusing on their pharmacological differences.
  • To discuss the clinical implications of these differences in antibiotic therapy.
  • To provide perspectives on optimizing polymyxin use in the context of antimicrobial resistance.

Main Methods:

  • Literature review of studies comparing polymyxin B and colistin.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Synthesis of clinical evidence and expert opinion.

Main Results:

  • Polymyxin B is administered as an active drug, while colistin is a pro-drug (colistimethate).
  • Significant differences exist in their potency and disposition profiles.
  • These distinctions impact their clinical efficacy and safety.

Conclusions:

  • Polymyxin B and colistin are not interchangeable due to inherent pharmacological differences.
  • Optimized dosing strategies are needed for both agents.
  • Careful consideration of their unique properties is essential for preserving their utility against resistant pathogens.